HealthWarehouse.com 2025 sales rise 46% on B2B prescription growth

HealthWarehouse.com

20/03/2026 12:16

Overview

US healthcare e-commerce platform's 2025 sales rose 46% yr/yr, driven by partner services growth

Net income turned positive for the year, while cash flow improved

Company expects 2026 sales to decline due to loss of authority to dispense GLP-1 medications

Outlook

Company expects positive cash flow from operations during 2026

HealthWarehouse.com says loss of authority to dispense GLP-1 medications will impact 2026 sales

Company is optimistic about new product launches and adding partners to offset sales decline

Result Drivers

B2B PRESCRIPTION GROWTH - Annual sales were driven by an 87% increase in partner services (B2B) prescription revenues, especially for brand and compounded GLP-1 medications

B2C PRESCRIPTION DECLINE - Direct-to-consumer prescription sales fell 24.3% in 2025 due to reduced sales of higher-cost branded medications and increased competition

GLP-1 SALES DROP - Q4 prescription sales declined, primarily due to lower sales of compounded GLP-1 medications

Company press release: ID:nBw1J5pnWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
$9.90 mln
Q4 Gross Margin
39.00%
Q4 Gross Profit
$3.80 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)